Martin D. Ryan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Martin D. Ryan has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Allison Robyn Pettit
Mater Research Institute-UQ, Translational Research Institute, Brisbane, Australia
1 shared publication - Antony Adamson
Genome Editing Unit, Faculty of Biology, Medicine and Health 4 , The University of Manchester, Manchester M13 9PT
1 shared publication - Anuj Sehgal
Mater Research Institute-The University of Queensland, The University of Queensland, Brisbane, Queensland, Australia
1 shared publication - Cheyenne J. Sandrock
Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, QLD 4102, Australia
1 shared publication - Clare Pridans
Institution for Regeneration and Repair, University of Edinburgh, Edinburgh, UK
1 shared publication - David Arthur Hume
Mater Research Institute-University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, Qld 4102, Australia
1 shared publication
Latest Publications
- Open Access
A transgenic line that reports CSF1R protein expression provides a definitive marker for the mouse mononuclear phagocyte system
The proliferation, differentiation and survival of cells of the mononuclear phagocyte system (MPS, progenitors, monocytes, macrophages and classical dendritic cells) is controlled by signals from the macrophage colony-stimulating factor receptor (CSF1R). Cells of the MPS lineage have been identified using numerous surface markers and transgenic reporters but none is both universal and lineage-restricted. Here we report the development and characterization of a novel CSF1R reporter mouse. A Fusion Red (FRed) cassette was inserted in-frame with the C-terminus of CSF1R, separated by a T2A-cleavable linker. The insertion had no effect of CSF1R expression or function. CSF1R-FRed was expressed in monocytes and macrophages and absent from granulocytes and lymphocytes. In bone marrow, CSF1R-FRed was absent in lineage-negative hematopoietic stem cells (HSC), arguing against a direct role for CSF1R in myeloid lineage commitment. It was highly-expressed in marrow monocytes and common myeloid progenitors (CMP) but significantly lower in granulocyte-macrophage progenitors (GMP). In sections of bone marrow, CSF1R-FRed was also detected in osteoclasts, CD169 + resident macrophages and, consistent with previous mRNA analysis, in megakaryocytes. In lymphoid tissues, CSF1R-FRed highlighted diverse MPS populations including classical dendritic cells. Whole mount imaging of non-lymphoid tissues in mice with combined CSF1R-FRed/ Csf1r -EGFP confirmed the restriction of CSF1R expression to MPS cells. The two markers highlight the remarkable abundance and regular distribution of tissue MPS cells including novel macrophage populations within tendon and skeletal muscle and underlying the mesothelial/serosal/capsular surfaces of every major organ. The CSF1R-FRed mouse provides a novel reporter with exquisite specificity for cells of the MPS.
Open AccessA transgenic line that reports CSF1R protein expression provides a definitive marker for the mouse mononuclear phagocyte system
The proliferation, differentiation and survival of cells of the mononuclear phagocyte system (MPS, progenitors, monocytes, macrophages and classical dendritic cells) is controlled by signals from the macrophage colony-stimulating factor receptor (CSF1R). Cells of the MPS lineage have been identified using numerous surface markers and transgenic reporters but none is both universal and lineage-restricted. Here we report the development and characterization of a novel CSF1R reporter mouse. A Fusion Red (FRed) cassette was inserted in-frame with the C-terminus of CSF1R, separated by a T2A-cleavable linker. The insertion had no effect of CSF1R expression or function. CSF1R-FRed was expressed in monocytes and macrophages and absent from granulocytes and lymphocytes. In bone marrow, CSF1R-FRed was absent in lineage-negative hematopoietic stem cells (HSC), arguing against a direct role for CSF1R in myeloid lineage commitment. It was highly-expressed in marrow monocytes and common myeloid progenitors (CMP) but significantly lower in granulocyte-macrophage progenitors (GMP). In sections of bone marrow, CSF1R-FRed was also detected in osteoclasts, CD169 + resident macrophages and, consistent with previous mRNA analysis, in megakaryocytes. In lymphoid tissues, CSF1R-FRed highlighted diverse MPS populations including classical dendritic cells. Whole mount imaging of non-lymphoid tissues in mice with combined CSF1R-FRed/ Csf1r -EGFP confirmed the restriction of CSF1R expression to MPS cells. The two markers highlight the remarkable abundance and regular distribution of tissue MPS cells including novel macrophage populations within tendon and skeletal muscle and underlying the mesothelial/serosal/capsular surfaces of every major organ. The CSF1R-FRed mouse provides a novel reporter with exquisite specificity for cells of the MPS.
- 9 August 2018
- Published by Wiley in Reviews in Medical Virology
- Vol. 28 (6) , e2001
“Therapeutic applications of the ‘NPGP’ family of viral 2As”
Summary: Oligopeptide “2A” and “2A‐like” sequences (“2As”; 18‐25aa) are found in a range of RNA virus genomes controlling protein biogenesis through “recoding” of the host‐cell translational apparatus. Insertion of multiple 2As within a single open reading frame (ORF) produces multiple proteins; hence, 2As have been used in a very wide range of biotechnological and biomedical applications. During translation, these 2A peptide sequences mediate a eukaryote‐specific, self‐“cleaving” event, termed “ribosome skipping” with very high efficiency. A particular advantage of using 2As is the ability to simultaneously translate a number of proteins at an equal level in all eukaryotic systems although, naturally, final steady‐state levels depend upon other factors—notably protein stability. By contrast, the use of internal ribosome entry site elements for co‐expression results in an unbalanced expression due to the relative inefficiency of internal initiation. For example, a 1:1 ratio is of particular importance for the biosynthesis of the heavy‐chain and light‐chain components of antibodies: highly valuable as therapeutic proteins. Furthermore, each component of these “artificial polyprotein” systems can be independently targeted to different sub‐cellular sites. The potential of this system was vividly demonstrated by concatenating multiple gene sequences, linked via 2A sequences, into a single, long, ORF—a polycistronic construct. Here, ORFs comprising the biosynthetic pathways for violacein (five gene sequences) and β‐carotene (four gene sequences) were concatenated into a single cistron such that all components were co‐expressed in the yeast Pichia pastoris. In this review, we provide useful information on 2As to serve as a guide for future utilities of this co‐expression technology in basic research, biotechnology, and clinical applications.
- 9 August 2018
- Published by Wiley in Reviews in Medical Virology
- Vol. 28 (6) , e2001
“Therapeutic applications of the ‘NPGP’ family of viral 2As”
Summary: Oligopeptide “2A” and “2A‐like” sequences (“2As”; 18‐25aa) are found in a range of RNA virus genomes controlling protein biogenesis through “recoding” of the host‐cell translational apparatus. Insertion of multiple 2As within a single open reading frame (ORF) produces multiple proteins; hence, 2As have been used in a very wide range of biotechnological and biomedical applications. During translation, these 2A peptide sequences mediate a eukaryote‐specific, self‐“cleaving” event, termed “ribosome skipping” with very high efficiency. A particular advantage of using 2As is the ability to simultaneously translate a number of proteins at an equal level in all eukaryotic systems although, naturally, final steady‐state levels depend upon other factors—notably protein stability. By contrast, the use of internal ribosome entry site elements for co‐expression results in an unbalanced expression due to the relative inefficiency of internal initiation. For example, a 1:1 ratio is of particular importance for the biosynthesis of the heavy‐chain and light‐chain components of antibodies: highly valuable as therapeutic proteins. Furthermore, each component of these “artificial polyprotein” systems can be independently targeted to different sub‐cellular sites. The potential of this system was vividly demonstrated by concatenating multiple gene sequences, linked via 2A sequences, into a single, long, ORF—a polycistronic construct. Here, ORFs comprising the biosynthetic pathways for violacein (five gene sequences) and β‐carotene (four gene sequences) were concatenated into a single cistron such that all components were co‐expressed in the yeast Pichia pastoris. In this review, we provide useful information on 2As to serve as a guide for future utilities of this co‐expression technology in basic research, biotechnology, and clinical applications.